# US 2015/0104510 A1 · Aliphatic Amine Polymer Salts for Tableting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104510 A1
- Document ID: US20150104510A1
- Status: Published application
- Kind: A1
- Application number: 14/326,877
- Filed: 2014-07-09
- Published: 2015-04-16
- Earliest claimed: 2004-11-01
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Hitesh R. Bhagat; Jeffrey M. Goldberg; Abizer I. Harianawala; Louis Brenner
- Web page: https://patentgrep.com/patent/US20150104510A1

## CPC

- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/785: Polymers containing nitrogen
- A61K 47/02: Inorganic compounds
- A61P 3/12: for electrolyte homeostasis
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 5/18: of the parathyroid hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 13/12: of the kidneys
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

A method of removing phosphate from a patient in need thereof, comprising administering a tablet comprising a tablet core and said table core comprising:
i) a therapeutically acceptable amount of sevelamer carbonate; and
ii) sodium chloride, wherein the chloride of the sodium chloride is present in a range of between 0.1 to 1% by weight relative to the combined weights of the sevelamer carbonate and the sodium chloride.

### Claim 50 (depends on 49)

The method of claim 49, wherein the sodium chloride is sodium chloride powder.

### Claim 51 (depends on 49)

The method of claim 49, wherein the chloride is present in a range of between 0.1 to 0.3% by weight relative to the combined weights of the sevelamer carbonate and the sodium chloride.

### Claim 52 (depends on 49)

The method of claim 49, wherein the tablet core further comprises one or more excipients.

### Claim 53 (depends on 52)

The method of claim 52, wherein the one or more excipients are selected from the group consisting of: colloidal silicon dioxide, stearic acid, magnesium silicate, calcium silicate, sucrose, cellulose, calcium stearate, glyceryl behenate, magnesium stearate, talc, zinc stearate, sodium stearylfumarate, carboxymethyl cellulose, microcrystalline cellulose, hydroxypropyl cellulose, acacia, tragacanth, pectin, gelatin, and polyethylene glycol.

### Claim 54 (depends on 52)

The method of claim 52, wherein the one or more excipients includes hypromellose.

### Claim 55 (depends on 52)

The method of claim 52, wherein the one or more excipients includes diacetylated monoglyceride.

### Claim 56 (depends on 52)

The method of claim 52, wherein the one or more excipients includes colloidal silicon dioxide.

### Claim 57 (depends on 52)

The method of claim 52, wherein the one or more excipients includes stearic acid.

### Claim 58 (depends on 52)

The method of claim 52, wherein the one or more excipients includes zinc stearate.

### Claim 59 (depends on 52)

The method of claim 52, wherein the one or more excipients includes microcrystalline cellulose.

### Claim 60 (depends on 49)

The method of claim 49, wherein the tablet is coated with a coating composition.

### Claim 61 (depends on 60)

The method of claim 60, wherein the coating composition comprises hydroxypropylmethylcellulose.

### Claim 62 (depends on 60)

The method of claim 60, wherein the coating composition further comprises a plasticizing agent.

### Claim 63 (depends on 49)

The method of claim 49, wherein the tablet core has a length and a width and the largest dimension of the tablet core is about 0.748 inches.

### Claim 64 (depends on 49)

The method of claim 49, wherein the tablet core diameter is no greater than 0.748 inches.

### Claim 65 (depends on 49)

The method of claim 49, wherein the tablet core diameter is 0.748 inches.

### Claim 66 (depends on 49)

The method of claim 49, wherein the tablet is an oval, film coated, compressed tablet.

### Claim 67 (depends on 66)

The method of claim 66, wherein the tablet comprises 800 mg of sevelamer carbonate on an anhydrous basis.

### Claim 68 (depends on 66)

The method of claim 66, wherein the tablet comprises 400 mg of sevelamer carbonate on an anhydrous basis.
